A phase II study of the PI3K inhibitor copanlisib in combination with the antiCD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: Treatment rationale and protocol design of the COUP-1 trial

Antiresorptive effect of a cathepsin K inhibitor ONO-5334 and its relationship to BMD increase in a phase II trial for postmenopausal osteoporosis

9 p | 10 | 2

Transhepatic arterial infusion chemotherapy using a combination of miriplatin and CDDP powder versus miriplatin alone in the treatment of hepatocellular carcinoma: A randomized controlled trial

9 p | 13 | 2

Higher rate of skin rash in a phase II trial with weekly nanoparticle albumin-bound paclitaxel and cisplatin combination in Chinese breast cancer patients

6 p | 13 | 2

Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses

10 p | 11 | 1

Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial

10 p | 7 | 1

PRognostic factor of Early Death In phase II Trials or the end of ‘sufficient life expectancy’ as an inclusion criterion? (PREDIT model)

8 p | 8 | 1

Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: A multicenter phase II study (TOSA trial) protocol

4 p | 22 | 1

A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: Clinical and biological features

9 p | 14 | 0

A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancer

9 p | 29 | 0